文献速递糖尿病肥胖与代谢综合征

Cotadutide双重受体激动剂的疗效、安全性与机制

Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

这项随机双盲2a期研究在65例超重/肥胖2型糖尿病患者中评估了GLP-1/胰高血糖素双受体激动剂cotadutide的疗效与机制。结果显示,与安慰剂相比,cotadutide显著降低混合餐耐量试验后血糖AUC0-4h和体重,并增加胰岛素AUC、延长胃排空时间,提示其降糖作用由胰岛素分泌增强和胃排空延迟介导。

要点

  • Cotadutide显著降低餐后血糖AUC0-4h和体重。
  • Cotadutide增加餐后胰岛素分泌并延长胃排空时间。
  • 降糖机制涉及胰岛素分泌增强和胃排空延迟。

核心结论

  • Cotadutide的降糖作用可能由增强胰岛素分泌和延迟胃排空所介导。

研究设计与样本

  • 随机、双盲、2a期研究,在5个临床试验中心的2个队列中进行。
  • 共65例成人超重/肥胖2型糖尿病患者,63例完成研究,2例因不良事件退出。
  • 干预为每日一次皮下注射cotadutide或安慰剂,持续49天,剂量50-300 µg按周(队列1)或双周(队列2)递增。

主要发现

  • 混合餐耐量试验后血糖AUC0-4h变化:cotadutide组最小二乘均值(90%CI)为-21.52%(-25.68, -17.37),安慰剂组为6.32%(0.45, 12.20),P < 0.001。
  • 体重变化:cotadutide组为-3.41%(-4.37, -2.44),安慰剂组为-0.08%(-1.45, 1.28),P = 0.002。
  • 混合餐耐量试验后胰岛素AUC0-4h变化:cotadutide组为19.3 mU.h/L(5.9, 32.6),P = 0.008。
  • 胃排空时间(半衰期)第43天:cotadutide组为117.2分钟,安慰剂组为-42.9分钟,P = 0.0392。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Cotadutide is a dual receptor agonist with balanced glucagon-like peptide-1 and glucagon activity. OBJECTIVE: To evaluate different doses of cotadutide and investigate underlying mechanisms for its glucose-lowering effects. DESIGN/SETTING: Randomized, double-blind, phase 2a study conducted in 2 cohorts at 5 clinical trial sites. PATIENTS: Participants were 65 adult overweight/obese patients with type 2 diabetes mellitus; 63 completed the study; 2 were withdrawn due to AEs. INTERVENTION: Once-daily subcutaneous cotadutide or placebo for 49 days. Doses (50-300 µg) were uptitrated weekly (cohort 1) or biweekly (cohort 2). MAIN OUTCOME MEASURES: Co-primary end points (cohort 1) were percentage changes from baseline to end of treatment in glucose (area under the curve from 0 to 4 hours [AUC0-4h]) post-mixed-meal tolerance test (MMTT) and weight. Exploratory measures included postprandial insulin and gastric emptying time (GET; cohort 2). RESULTS: Patients received cotadutide (cohort 1, n = 26; cohort 2, n = 20) or placebo (cohort 1, n = 13; cohort 2, n = 6). Significant reductions were observed with cotadutide vs placebo in glucose AUC0-4h post MMTT (least squares mean [90% CI], -21.52% [-25.68, -17.37] vs 6.32% [0.45, 12.20]; P < 0.001) and body weight (-3.41% [-4.37, -2.44] vs -0.08% [-1.45, 1.28]; P = 0.002). A significant increase in insulin AUC0-4h post MMTT was observed with cotadutide (19.3 mU.h/L [5.9, 32.6]; P = 0.008) and GET was prolonged on day 43 with cotadutide vs placebo (t½: 117.2 minutes vs -42.9 minutes; P = 0.0392). CONCLUSION: These results suggest that the glucose-lowering effects of cotadutide are mediated by enhanced insulin secretion and delayed gastric emptying. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03244800.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Parker VER, Robertson D, Wang T, et al. Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist. J Clin Endocrinol Metab. 2020. PMID: 31608926. doi:10.1210/clinem/dgz047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。